Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,710 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Patent Foramen Ovale (PFO) Closure in Japan　- 30-Day Clinical Outcomes From the AmplatzerTM PFO Occluder Japan Post-Marketing Surveillance Study.
Akagi T, Hara H, Kanazawa H, Fukui S, Hashimoto Y, Iguchi Y, Iwama T, Kataoka H, Kawamura A, Kawano H, Oki K, Yamagami H; PFO Japan PMS Investigators. Akagi T, et al. Among authors: hara h. Circ J. 2024 May 11. doi: 10.1253/circj.CJ-24-0080. Online ahead of print. Circ J. 2024. PMID: 38735702 Free article.
Correction: Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study.
WakasakiI T, Manako T, YasumatsuI R, Hara H, Toh S, Masuda M, YamauchiID M, Kuratomi Y, Nishimura E, Takeuchi T, Matsuo M, Jiromaru R, Hashimoto K, Komune N, Nakagawa T. WakasakiI T, et al. Among authors: hara h. PLoS One. 2024 May 9;19(5):e0303720. doi: 10.1371/journal.pone.0303720. eCollection 2024. PLoS One. 2024. PMID: 38722895 Free PMC article.
Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data.
Tomida R, Takahashi M, Matsushita Y, Kojima T, Yamana K, Kandori S, Bando Y, Nishiyama N, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Tatarano S, Masui K, Matsuda A, Kaneko T, Motoshima T, Shiraishi Y, Kira S, Murashima T, Hara H, Matsumura M, Kitamura H, Miyake H, Furukawa J; Japanese Urological Oncology Group. Tomida R, et al. Among authors: hara h. Clin Genitourin Cancer. 2024 Apr 15:102094. doi: 10.1016/j.clgc.2024.102094. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38714434
H1FOO-DD promotes efficiency and uniformity in reprogramming to naive pluripotency.
Kunitomi A, Hirohata R, Osawa M, Washizu K, Arreola V, Saiki N, Kato TM, Nomura M, Kunitomi H, Ohkame T, Ohkame Y, Kawaguchi J, Hara H, Kusano K, Yamamoto T, Takashima Y, Tohyama S, Yuasa S, Fukuda K, Takasu N, Yamanaka S. Kunitomi A, et al. Among authors: hara h. Stem Cell Reports. 2024 Apr 23:S2213-6711(24)00111-5. doi: 10.1016/j.stemcr.2024.04.005. Online ahead of print. Stem Cell Reports. 2024. PMID: 38701780 Free article.
Innate phase production of IFN-γ by memory and effector T cells expressing early activation marker CD69 during infection with Cryptococcus deneoformans in the lungs.
Miyahara A, Umeki A, Sato K, Nomura T, Yamamoto H, Miyasaka T, Tanno D, Matsumoto I, Zong T, Kagesawa T, Oniyama A, Kawamura K, Yuan X, Yokoyama R, Kitai Y, Kanno E, Tanno H, Hara H, Yamasaki S, Saijo S, Iwakura Y, Ishii K, Kawakami K. Miyahara A, et al. Among authors: hara h. Infect Immun. 2024 May 3:e0002424. doi: 10.1128/iai.00024-24. Online ahead of print. Infect Immun. 2024. PMID: 38700335
3,710 results